Northwestern Mutual Investment Management Company LLC trimmed its stake in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 5.8% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,585 shares of the life sciences company’s stock after selling 779 shares during the period. Northwestern Mutual Investment Management Company LLC’s holdings in Integra Lifesciences were worth $701,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. grew its holdings in shares of Integra Lifesciences by 3.2% in the fourth quarter. BlackRock Inc. now owns 6,730,304 shares of the life sciences company’s stock worth $303,536,000 after purchasing an additional 210,960 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Integra Lifesciences by 31.5% during the 1st quarter. Janus Henderson Group PLC now owns 2,873,324 shares of the life sciences company’s stock worth $160,102,000 after acquiring an additional 688,761 shares in the last quarter. Oregon Public Employees Retirement Fund grew its holdings in Integra Lifesciences by 4,410.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,254,051 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 1,226,245 shares in the last quarter. Brown Advisory Inc. bought a new position in Integra Lifesciences during the 4th quarter worth about $45,653,000. Finally, Geode Capital Management LLC grew its holdings in Integra Lifesciences by 5.7% during the 4th quarter. Geode Capital Management LLC now owns 731,431 shares of the life sciences company’s stock worth $32,987,000 after acquiring an additional 39,637 shares in the last quarter. 82.27% of the stock is owned by hedge funds and other institutional investors.
Several brokerages have issued reports on IART. ValuEngine cut shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a report on Thursday, April 18th. Zacks Investment Research cut shares of Integra Lifesciences from a “buy” rating to a “hold” rating and set a $56.00 price target on the stock. in a report on Thursday, June 20th. BidaskClub cut shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a report on Tuesday, April 16th. Finally, Oppenheimer decreased their price objective on shares of Integra Lifesciences from $70.00 to $65.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company. Integra Lifesciences currently has an average rating of “Hold” and a consensus price target of $58.64.
Shares of NASDAQ:IART traded down $0.43 during trading on Monday, hitting $55.42. 739,600 shares of the stock traded hands, compared to its average volume of 478,039. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.86 and a current ratio of 2.86. The stock has a market capitalization of $4.84 billion, a P/E ratio of 22.90, a price-to-earnings-growth ratio of 1.68 and a beta of 1.07. The business’s fifty day simple moving average is $50.49. Integra Lifesciences Holdings Corp has a 52-week low of $42.14 and a 52-week high of $66.41.
Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings results on Wednesday, April 24th. The life sciences company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.04. Integra Lifesciences had a net margin of 5.60% and a return on equity of 15.60%. The firm had revenue of $359.69 million for the quarter, compared to analysts’ expectations of $361.12 million. During the same quarter last year, the company earned $0.58 EPS. The firm’s revenue for the quarter was up .7% compared to the same quarter last year. As a group, equities research analysts anticipate that Integra Lifesciences Holdings Corp will post 2.7 EPS for the current fiscal year.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.